APLS
Price
$22.37
Change
+$0.15 (+0.68%)
Updated
Sep 26 closing price
Capitalization
2.83B
43 days until earnings call
IMAB
Price
$3.48
Change
-$0.04 (-1.14%)
Updated
Sep 26 closing price
Capitalization
401.13M
46 days until earnings call
Interact to see
Advertisement

APLS vs IMAB

Header iconAPLS vs IMAB Comparison
Open Charts APLS vs IMABBanner chart's image
Apellis Pharmaceuticals
Price$22.37
Change+$0.15 (+0.68%)
Volume$2.77M
Capitalization2.83B
I-MAB
Price$3.48
Change-$0.04 (-1.14%)
Volume$288.29K
Capitalization401.13M
APLS vs IMAB Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. IMAB commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and IMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (APLS: $22.37 vs. IMAB: $3.48)
Brand notoriety: APLS and IMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 107% vs. IMAB: 11%
Market capitalization -- APLS: $2.83B vs. IMAB: $401.13M
APLS [@Biotechnology] is valued at $2.83B. IMAB’s [@Biotechnology] market capitalization is $401.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileIMAB’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • IMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, IMAB is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while IMAB’s TA Score has 2 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 5 bearish.
  • IMAB’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, APLS is a better buy in the short-term than IMAB.

Price Growth

APLS (@Biotechnology) experienced а -2.78% price change this week, while IMAB (@Biotechnology) price change was -8.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

APLS is expected to report earnings on Nov 10, 2025.

IMAB is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.83B) has a higher market cap than IMAB($401M). IMAB YTD gains are higher at: 309.412 vs. APLS (-29.897). IMAB has higher annual earnings (EBITDA): -36.89M vs. APLS (-178.43M). APLS has more cash in the bank: 370M vs. IMAB (166M). IMAB has less debt than APLS: IMAB (3.48M) vs APLS (470M). APLS has higher revenues than IMAB: APLS (755M) vs IMAB (0).
APLSIMABAPLS / IMAB
Capitalization2.83B401M704%
EBITDA-178.43M-36.89M484%
Gain YTD-29.897309.412-10%
P/E RatioN/AN/A-
Revenue755M0-
Total Cash370M166M223%
Total Debt470M3.48M13,502%
FUNDAMENTALS RATINGS
APLS: Fundamental Ratings
APLS
OUTLOOK RATING
1..100
51
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
APLSIMAB
RSI
ODDS (%)
Bullish Trend 3 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
76%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSANF2.550.09
+3.46%
Nissan Motor Co., Ltd.
MMTMF0.460.01
+1.48%
Monument Mining Ltd.
IPSOF43.50N/A
N/A
IPSOS
SABOF0.31N/A
N/A
Sabio Holdings Inc.
RHHBY39.59-0.37
-0.93%
Roche Holding Ltd

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with DNLI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+0.68%
DNLI - APLS
48%
Loosely correlated
+3.87%
DYN - APLS
43%
Loosely correlated
+4.53%
VTYX - APLS
40%
Loosely correlated
+10.78%
ARWR - APLS
40%
Loosely correlated
+3.60%
CRNX - APLS
40%
Loosely correlated
+27.92%
More

IMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with INDP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then INDP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
-1.14%
INDP - IMAB
38%
Loosely correlated
+6.40%
LYRA - IMAB
34%
Loosely correlated
+1.73%
RPRX - IMAB
31%
Poorly correlated
+0.40%
TPST - IMAB
28%
Poorly correlated
+0.75%
APLS - IMAB
27%
Poorly correlated
+0.68%
More